Detalles de la búsqueda
1.
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
Int J Colorectal Dis
; 32(8): 1179-1190, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28424871
2.
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
Br J Cancer
; 115(10): 1206-1214, 2016 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27736842
3.
[IFTIR study on the micro-structure in the construction process of water-borne coatings].
Guang Pu Xue Yu Guang Pu Fen Xi
; 34(2): 354-7, 2014 Feb.
Artículo
en Zh
| MEDLINE | ID: mdl-24822400
4.
Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Clin Ther
; 31(4): 806-15, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19446153
5.
Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma.
ESMO Open
; 3(2): e000297, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29531837
6.
Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Clin Colorectal Cancer
; 17(3): 206-214, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29703606
7.
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Clin Ther
; 29(1): 139-53, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17379054
8.
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Diabetes Technol Ther
; 9(4): 317-26, 2007 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-17705687
9.
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Eur J Cancer
; 68: 51-59, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27716478
10.
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Curr Med Res Opin
; 24(10): 2943-52, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18786299
11.
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Curr Med Res Opin
; 24(1): 275-86, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18053320
Resultados
1 -
11
de 11
1
Próxima >
>>